Overview

Comprehensive FDA-approved therapies for Mycosis Fungoides (CTCL) including targeted agents, immunotherapy, and combination regimens. Treatment approaches vary by molecular subtype, stage, and biomarker status.

Epidemiology & Impact

Mycosis fungoides is the most common cutaneous T-cell lymphoma, accounting for 50% of primary cutaneous lymphomas. Annual incidence is 5-6 per million. It has a 2:1 male predominance, median age 55-60, and higher incidence in Black populations. The disease typically follows an indolent course through patch, plaque, and tumor stages over years. Early-stage disease has 10-year survival exceeding 80%.

Molecular Biology & Biomarkers

MF arises from skin-homing CD4+ T cells. Molecular features include CDKN2A deletions, TP53 mutations, and JAK-STAT pathway activation (STAT3, STAT5B). T-cell receptor clonal rearrangement serves as a diagnostic tool. The microenvironment shifts from Th1 to Th2 dominance as disease advances, causing progressive immunosuppression.

Evolving Treatment Landscape

Treatment follows a stage-adapted approach. Early-stage uses skin-directed therapies: topical corticosteroids, phototherapy (PUVA, narrowband UVB), and nitrogen mustard. Advanced disease options include brentuximab vedotin (CD30-positive), mogamulizumab (anti-CCR4), HDAC inhibitors (vorinostat, romidepsin), and bexarotene. Extracorporeal photopheresis is used for erythrodermic disease.

Approved Mycosis Fungoides / Sézary Syndrome Therapies

Adcetris
brentuximab vedotin
FDA Approved 2017 CD30+ after prior systemic therapy
Approved Indications (US/FDA)
Treatment of adult patients with primary cutaneous anaplastic large cell lymphoma or CD30-expressing mycosis fungoides who have received prior systemic therapy.
Dosing Schedule
1.8 mg/kg IV every 3 weeks (max 180 mg)
Drug Class
ADC (Anti-CD30)
Manufacturer
Seagen/Takeda
Approval Year
2017
Pivotal Trial
NCT01578499 ↗
Key Publication
Prince et al. Lancet 2017 (ALCANZA) ↗
Poteligeo
mogamulizumab-kpkc
FDA Approved 2018 R/R after ≥1 prior systemic therapy
Approved Indications (US/FDA)
Treatment of adult patients with relapsed or refractory mycosis fungoides or Sézary syndrome after at least one prior systemic therapy.
Dosing Schedule
1 mg/kg IV on Days 1, 8, 15, 22 of first 28-day cycle; then Days 1, 15 of subsequent cycles
Drug Class
Anti-CCR4 Monoclonal Antibody
Manufacturer
Kyowa Kirin
Approval Year
2018
Pivotal Trial
NCT01728805 ↗
Key Publication
Kim et al. Lancet Oncol 2018 (MAVORIC) ↗
Targretin
bexarotene
FDA Approved 1999 R/R CTCL
Approved Indications (US/FDA)
Treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.
Dosing Schedule
300 mg/m²/day orally once daily
Drug Class
Retinoid (RXR Agonist)
Manufacturer
Bausch Health
Approval Year
1999
Key Publication
Istodax
romidepsin
FDA Approved 2009 2nd Line+
Approved Indications (US/FDA)
Treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy.
Dosing Schedule
14 mg/m² IV over 4 hours on days 1, 8, and 15 of a 28-day cycle
Cycle Length
28-day cycles
Combination Therapy
Monotherapy (histone deacetylase inhibitor)
Manufacturer
Celgene/BMS
Approval Year
2009
Pivotal Trial
NCT00007345 ↗
Key Publication
Piekarz et al. JCO 2009 ↗
Zolinza
vorinostat
FDA Approved 2006 2nd Line+
Approved Indications (US/FDA)
Treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent, or recurrent disease on or following two systemic therapies.
Dosing Schedule
400 mg orally once daily with food
Cycle Length
Continuous daily dosing
Combination Therapy
Monotherapy (histone deacetylase inhibitor)
Manufacturer
Merck
Approval Year
2006
Pivotal Trial
NCT00091559 ↗
Key Publication
Olsen et al. JCO 2007 ↗
Duvic et al. JCO 2001 ↗